Navigation Links
Rockefeller University's Center for Clinical and Translational Science funds pilot studies
Date:1/7/2008

The Rockefeller University Center for Clinical and Translational Science (CCTS) has announced the recipients of its 2008 Pilot Project grants. Eight Rockefeller researchers will each receive $25,000 from the center to fund early studies in translational science that, if successful, might lead to clinical trials. The CCTS and the grant program are in their second year, established through funds from a Clinical and Translational Science Award the university received from the National Center for Research Resources of the National Institutes of Health. In its first year, the program provided $165,000 for nine clinical studies.

The centers administration selected the 2008 pilot projects from among proposals submitted in the fall. The recipients are:

  • Marina Caskey, an instructor in clinical investigation, to compare the efficacy of poly IC and Ampligen as adjuvants for an HIV vaccine targeted at DEC-205, an antigen receptor on dendritic cells.

  • Delivette Castor, instructor in clinical investigation, to apply demographic, psychosocial, sexual and drug use history and other data gathered from 280 men who have sex with men to examine the roles of these factors in the risk of HIV-1 infection and transmitted drug resistance.

  • Mouquet Hugo, postdoctoral fellow in Michel Nussenzweigs Laboratory of Molecular Immunology, to elucidate the etiology of Pemphigus vulgaris, a life-threatening autoimmune disease affecting skin and mucosa, by comparing repertoires of autoreactive and polyreactive B cells in patients with the disease to those of healthy volunteers.

  • Igor Kravets, instructor in clinical investigation, to examine the mechanism of action of disulfiram, a drug commonly used to treat chronic alcoholism, with regard to cocaine addiction.

  • Jan Lunemann, postdoctoral fellow in Christian Mnzs Laboratory of Viral Immunobiology, to test the hypothesis that a cause of multiple sclerosis is an aberrant response of the central nervous system to the Epstein Barr virus on the level of virus-infected B cells.

  • Lisa Neff, instructor in clinical investigation, to test the hypothesis that the Dietary Approaches to Stop Hypertension diet and the low glycemic index diet improve insulin sensitivity in patients with insulin resistance and/or metabolic syndrome.

  • Swaroop Pendyala, instructor in clinical investigation, to determine if significant weight loss achieved by dieting decreases chronic inflammation in the colorectal epithelium and reduces fecal calprotectin levels.

  • Alexander Ploss, postdoctoral associate in Charles Rices Laboratory of Virology and Infectious Disease, to generate patient-specific human hepatocytes as a renewable source for primary liver tissue.


'/>"/>

Contact: Joseph Bonner
bonnerj@rockefeller.edu
212-327-8998
Rockefeller University
Source:Eurekalert

Related medicine news :

1. National Patient Advocate Foundation Hails Senator Rockefeller for Introducing Bill Protecting Patient Access to Health Coverage
2. Columbia Center for Childrens Environmental Health receives NIEHS grant to study asthma
3. Parkway Clinical Laboratories Expands Management Team to Support a National Growth Strategy Centered on Oral Fluid Drug Screening
4. Susan G. Komen for the Cure, Ryan Community Health Centers, Breast Cancer Survivors Call on New York State to Expand Breast Cancer Screening, Treatment Programs
5. Language centers revealed, brain surgery refined with new mapping
6. Brown named Center of Excellence in Geriatric Medicine and Training
7. American College of Physicians receives grant to study cost of patient-centered medical home
8. Americas Blood Centers Thanks Donors During Celebration of National Blood Donor Month
9. Grubb & Ellis Healthcare REIT Acquires Chesterfield Rehabilitation Center in Chesterfield, Missouri in a Joint Venture with Duke Realty
10. Fitworks West Chester Mega-Center Now Open
11. National Drug Intelligence Center Releases 2008 National Methamphetamine Threat Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Ontario (PRWEB) , ... September 19, 2017 , ... Public ... regulation of pollutants have fallen on deaf ears, leaving the water industry itself to ... company that stays ahead of the curve in the field of natural alkaline ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone Solutions Inc. (BSI), an ... orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist with ... magnesium, a critical property for bone health and development. , “We’re excited to ...
(Date:9/19/2017)... ... , ... Ron Norman, CEO of Team Decades, http://www.teamdecades.com , stressed to ... than generic impression in the job market if one is looking for career expansion. ... that the first impression they give off is not a good one," says Norman, ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency nursing expertise, skill set, ... Nurse (CEN®) certification according to a large-scale study announced today by the ... by the Human Resources Research Organization (HumRRO) in late 2016 and early 2017, ...
(Date:9/18/2017)... ... ... A September 7 article on BBC News describes new research ... most common and least expensive medications, may be able to stimulate stem cells and ... Dental Group and Calabasas Dental Care says that, while it’s likely to be some ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a leader ... will host an educational session focused on the role ... (CLABSI) prevention at the 2017 Annual Scientific Meeting of ... take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s Prevantics® ...
(Date:9/5/2017)... Sept. 5, 2017  Getinge, a leading global ... vibrant charitable donation program -- "Color for the ... heart defect research by The Children,s Heart Foundation. ... general public are encouraged to download a coloring ... completed artwork to the gallery on the website. ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
Breaking Medicine Technology: